HALO Stock Forecast 2025-2026
Distance to HALO Price Targets
HALO Price Momentum
10 Quality Stocks Worth Considering Now
Researching Halozyme (HALO) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on HALO and similar high-potential opportunities.
Latest HALO Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, HALO has a bullish consensus with a median price target of $69.50 (ranging from $58.00 to $78.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $59.25, the median forecast implies a 17.3% upside. This outlook is supported by 6 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Jessica Fye at JP Morgan, suggesting a 2.1% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HALO Analyst Ratings
HALO Price Target Range
Latest HALO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HALO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | JP Morgan | Jessica Fye | Neutral | Maintains | $58.00 |
| Mar 6, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $0.00 |
| Feb 20, 2025 | Benchmark | Robert Wasserman | Buy | Reiterates | $75.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $72.00 |
| Feb 4, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $70.00 |
| Jan 13, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $57.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $70.00 |
| Jan 10, 2025 | Piper Sandler | Joseph Catanzaro | Neutral | Maintains | $53.00 |
| Dec 30, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $68.00 |
| Dec 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $68.00 |
| Nov 25, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $68.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $68.00 |
| Nov 4, 2024 | Piper Sandler | Joseph Catanzaro | Neutral | Maintains | $52.00 |
| Nov 1, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $68.00 |
| Nov 1, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $73.00 |
| Oct 25, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
| Oct 7, 2024 | Wells Fargo | Mohit Bansal | Equal-Weight | Downgrade | $62.00 |
| Oct 4, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
| Sep 19, 2024 | JP Morgan | Jessica Fye | Neutral | Downgrade | $57.00 |
| Sep 16, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $65.00 |
Halozyme Therapeutics Inc. (HALO) Competitors
The following stocks are similar to Halozyme based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Halozyme Therapeutics Inc. (HALO) Financial Data
Halozyme Therapeutics Inc. has a market capitalization of $7.22B with a P/E ratio of 17.0x. The company generates $1.02B in trailing twelve-month revenue with a 43.7% profit margin.
Revenue growth is +29.5% quarter-over-quarter, while maintaining an operating margin of +58.9% and return on equity of +198.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Halozyme Therapeutics Inc. (HALO) Business Model
About Halozyme Therapeutics Inc.
Develops innovative drug delivery technologies.
Halozyme Therapeutics partners with major pharmaceutical companies to integrate its proprietary ENHANZE technology into various treatments, enhancing subcutaneous drug delivery. The company generates revenue through collaborations and licensing agreements, allowing it to monetize its technology across multiple therapeutic areas such as oncology, immunology, and genetic disorders.
Based in San Diego, California, Halozyme is recognized for its contributions to improving patient experiences and medical outcomes in the biopharmaceutical industry. The company's focus on enhancing drug absorption and reducing intravenous needs positions it as a significant player in the evolving landscape of drug delivery solutions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
350
CEO
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Country
United States
IPO Year
2004
Website
halozyme.comHalozyme Therapeutics Inc. (HALO) Latest News & Analysis
Latest News
Halozyme Therapeutics filed a patent infringement lawsuit against Merck, claiming its Keytruda cancer treatment violates Halozyme's MDASE technology patents.
The lawsuit could impact Merck's Keytruda sales and development costs, affecting its stock price. Halozyme's potential damages could also influence its market position and investor sentiment.
Halozyme shares have rebounded from their 200-day support level, demonstrating relative strength in a volatile market where many stocks are underperforming.
Halozyme's stock finding support at the 200-day line indicates resilience and potential for recovery, signaling a bullish trend amid broader market volatility, which may attract investor interest.
Halozyme Therapeutics announced FDA approval for argenx's VYVGART® Hytrulo, a self-injection treatment for adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
The FDA approval of VYVGART® Hytrulo expands treatment options for gMG and CIDP, potentially increasing market demand and revenue for argenx, impacting investor sentiment positively.
Halozyme Therapeutics announced that Janssen-Cilag received EC marketing authorization for RYBREVANT® and LAZCLUZE® for treating advanced NSCLC in specific patient populations.
The EC approval of RYBREVANT and LAZCLUZE could boost Halozyme's revenue through royalties or partnerships, positively impacting its stock performance and market position in oncology.
Halozyme Therapeutics announced that the European Commission approved an expanded indication for DARZALEX® (daratumumab) subcutaneous formulation in treating newly diagnosed multiple myeloma.
Approval of DARZALEX with ENHANZE technology enhances its market position in multiple myeloma treatment, potentially increasing sales and benefiting Halozyme's stock performance.
The top five biotech stocks today share strong ratings, indicating favorable evaluations in the market.
Strong ratings for top biotech stocks indicate potential growth and stability, attracting investor interest and possibly driving stock prices higher.
Frequently Asked Questions About HALO Stock
What is Halozyme Therapeutics Inc.'s (HALO) stock forecast for 2025?
Based on our analysis of 17 Wall Street analysts, Halozyme Therapeutics Inc. (HALO) has a median price target of $69.50. The highest price target is $78.00 and the lowest is $58.00.
Is HALO stock a good investment in 2025?
According to current analyst ratings, HALO has 6 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $59.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HALO stock?
Wall Street analysts predict HALO stock could reach $69.50 in the next 12 months. This represents a 17.3% increase from the current price of $59.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Halozyme Therapeutics Inc.'s business model?
Halozyme Therapeutics partners with major pharmaceutical companies to integrate its proprietary ENHANZE technology into various treatments, enhancing subcutaneous drug delivery. The company generates revenue through collaborations and licensing agreements, allowing it to monetize its technology across multiple therapeutic areas such as oncology, immunology, and genetic disorders.
What is the highest forecasted price for HALO Halozyme Therapeutics Inc.?
The highest price target for HALO is $78.00 from at , which represents a 31.6% increase from the current price of $59.25.
What is the lowest forecasted price for HALO Halozyme Therapeutics Inc.?
The lowest price target for HALO is $58.00 from Jessica Fye at JP Morgan, which represents a -2.1% decrease from the current price of $59.25.
What is the overall HALO consensus from analysts for Halozyme Therapeutics Inc.?
The overall analyst consensus for HALO is bullish. Out of 17 Wall Street analysts, 6 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $69.50.
How accurate are HALO stock price projections?
Stock price projections, including those for Halozyme Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.